No Data
TYK MEDICINES-B: Annual Report 2024
TYK MEDICINES-B plans to invest 18 million yuan to establish a Fund focusing on investing in the biopharmaceutical Business.
TYK MEDICINES-B (02410) announced that on April 24, 2025, the company entered into a partnership agreement with Tengyuan Changxing, Huzhou Innovation, Huzhou Industrial Investment, Changxing Xingchang Investment, and Shanghai Younan. According to this agreement, the parties agree to establish a Fund, with the company participating as a limited partner in the newly established Fund. Under the partnership agreement, the company agrees to invest 18 million yuan into the Fund. The Fund will primarily focus on early development projects in the Biomedical Industry, while also considering growth-stage Biomedical projects. The Fund will adhere to an investment strategy that combines venture capital, Private Equity, and merger and acquisition investments, with its investment areas being...
TYK MEDICINES-B (02410) plans to invest 18 million yuan to establish a Fund focused on investing in the Business of biopharmaceuticals.
TYK MEDICINES-B (02410) announced that on April 24, 2025, the company will collaborate with Tengyuan Changxing and Huzhou Chuang...
Express News | Tyk Medicines Inc - to Invest RMB18.0 Mln in Limited Partnership Fund Set up as per Joint Venture Agreement
The submission of the Pre-NDA application for Alectinib tablets (TY-9591).
This drug is expected to become the world's first third-generation EGFR-TKI targeting patients with brain metastases from non-small cell lung cancer (NSCLC).
Tongyuan Kang Pharmaceutical (02410) TY-9591 selected for ASCO, a breakthrough achieved by local Innovative Drugs companies.
The latest research results of TY-9591, a core product of TYK MEDICINES-B (02410), were selected for the report at the 2025 American Society of Clinical Oncology (ASCO) conference.